Skip to main content
Figure 5 | Journal of Hematology & Oncology

Figure 5

From: Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma

Figure 5

Survival and organ infiltration in the peri-implantation model of disseminated MCL. (A) Anti-human CCR7 mAb significantly increases the survival of xenografted mice. Kaplan-Meier estimates of overall survival of mice treated with the anti-CCR7 mAb. Granta-519 cells were implanted intravenously in the vein tail of NOD/SCID mice (n = 10). Treatment with 200 μg of the anti-CCR7 mAb (■) or with PBS () started at day 2 post-inoculation and continued at days 6 and 10. (B) and (C) Anti-human CCR7 mAb significantly reduces the infiltration of lymphoid and distant organs. (B) One million cells from spleen, bone marrow and ovaries were harvested and incubated with anti-human-CD20 and the respective irrelevant isotype control. Then the percentage of xenografted CD20+ Granta-519 cells migrated to bone marrow, spleen and ovaries are shown. P-values refer to the differences of infiltration in tissues from PBS- and anti-CCR7 mAb-treated mice. Each black dot (, control group) or black square (■, treated group) represents one individual mouse. Horizontal bars represent mean percentage of xenografted CD20+ Granta-519 cells of each group, which consisted of 5 mice. (C) Immunohistochemistry assays with anti-human CD20 mAb were performed in tissue sections from brain, spine and lungs. Representative pictures from both a control mouse and an anti-CCR7- treated mouse are shown.

Back to article page